Galderma, a Swiss drugmaker focused on dermatology products, is in the preliminary stages of building a manufacturing facility in Singapore that would support its growth in the Asia-Pacific region.
While financial and other details weren’t disclosed, the company said the plant would feature a “high degree” of digital and automated features. The facility would be Galderma’s fifth manufacturing site, the company said Thursday.
Galderma is expanding in part thanks to strong growth for its dermo-cosmetics franchise, which grew revenues 31% year over year in the first half of 2022. The company's Cetaphil skin cleanser along with product launches in China and the rest of Asia contributed to the increase.
“Our goal is to support our strong growth trajectory in the long-term with a new manufacturing plant that will significantly increase our capacity to serve consumers with premium brands from our differentiated dermo-cosmetics portfolio across geographies, and primarily throughout our key markets in Asia-Pacific,” Flemming Ørnskov, M.D., Galderma’s chief executive, said in the press release.
Meanwhile, in June, the company announced a pair of phase 3 wins for its liquid formulation botulinum toxin A, a formulation is designed to eliminate the need to reconstitute the aesthetic treatment from powder.
At the time, Galderma said it plans to submit the data to U.S. and global regulatory authorities. European authorities gave a positive decision to Galderma’s liquid, ready-to-use botulinum toxin type A formulation last year.